Tuesday, November 2, 2021

Sanofi’s hopes for rare blood disease candidate sutimlimab on hold after FDA blasts 3rd-party manufacturer


When a new drug goes in front of the FDA for consideration, a lot of moving pieces must be in place for a successful review—manufacturing standards included. That didn’t happen for Sanofi, which is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer’s plant.

The FDA blasted a third-party manufacturer of Sanofi’s rare blood disease drug sutimlimab in a complete response letter, citing “certain deficiencies” at the contractor’s site, the French drugmaker said Friday. 

A Sanofi spokeswoman declined to specify who the manufacturer cited in the FDA’s letter was or what the nature of the deficiencies were.  

Whitepaper

The Rise of HPAPI Molecules – Trends in Highly Potent API Manufacturing

Highly potent active pharmaceutical ingredients are increasing in pharma pipelines. Lonza offers all HPAPI-related expertise to support your product development from concept to commercial use in an integrated manner.

With its application on hold, Sanofi said it would work with its manufacturer and the FDA to resolve the issues in a “timely manner.” The drugmaker didn’t say how quickly it expected to turn around a new application. 

The untimely feedback from the FDA dims C1 inhibitor sutimlimab’s chances in cold agglutinin disease (CAD), a rare blood disease characterized by anemia, fatigue and other symptoms. 

RELATED: Sanofi nabs speedy review of sutimlimab, aiming for a November approval

In May, the FDA accepted Sanofi’s sutimlimab application under priority review based on the strength of the drug’s pivotal phase 3 data, Sanofi believed. Those results, unveiled in late 2019, showed 13 of the 24 patients treated with sutimlimab after 26 weeks met the study’s primary endpoint, a composite assessment that looked at hemoglobin and freedom from transfusions.

Close to two-thirds of participants met the hemoglobin part of the endpoint, indicating they either experienced a 2 g/dL increase from baseline or ended the study with 12 g/dL or higher, a level that is at the bottom of the normal range for women and just below it for men. More than two-thirds of the subjects were free from transfusions from week five onward.

The FDA’s letter did not target sutimlimab’s clinical findings or safety, Sanofi noted in a release.

RELATED: Nabriva hit with another FDA setback with complete response letter for antibiotic Contepo



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...